Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

News Daily News

Proximity to Physical Activity Facilities May Play Role in Body Fat Levels

Michael O'Riordan

December 13, 2017

News Daily News

Ditching Desflurane Could Help Reduce Carbon Footprint of Surgical Procedures

L.A. McKeown

December 08, 2017

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Daily News

New Heart Failure Cases Rising Among Older Adults, MI Survivors

L.A. McKeown

November 24, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Four

Shelley Wood

November 02, 2017

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Presentation TCT 2017

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Stephen G. Ellis

October 31, 2017

News Daily News

Perfect Timing? Afternoon Valve Surgeries Have Fewer Complications

Michael O'Riordan

October 27, 2017

News Daily News

As Hypertension Sweeps China, Awareness, Treatment, and Control Remain Poor

Todd Neale

October 26, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Daily News

‘A Healthy Brexit’? How a Split From EU Could Affect UK Health System

Yael L. Maxwell

October 02, 2017

News Daily News

Physical Activity of Any Ilk Cuts CVD, Deaths in Global Study: PURE

Shelley Wood

September 22, 2017

News Daily News

Ischemic Heart Disease the Leading Cause of Death Globally

Michael O'Riordan

September 19, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

Advertisement

Proximity to Physical Activity Facilities May Play Role in Body Fat Levels

Ditching Desflurane Could Help Reduce Carbon Footprint of Surgical Procedures

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

New Heart Failure Cases Rising Among Older Adults, MI Survivors

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Live From Denver: TCT 2017, Day Four

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Perfect Timing? Afternoon Valve Surgeries Have Fewer Complications

As Hypertension Sweeps China, Awareness, Treatment, and Control Remain Poor

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

‘A Healthy Brexit’? How a Split From EU Could Affect UK Health System

Physical Activity of Any Ilk Cuts CVD, Deaths in Global Study: PURE

Ischemic Heart Disease the Leading Cause of Death Globally

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content